Abstract 2421: SOD1 is required for tumor maintenance in a genetically engineered KRAS/TP53 non-small cell lung cancer mouse model

Abstract

Abstract Lung cancer is the second most common cancer and the primary cause of cancer-related mortality globally. Over half a million people are estimated living with lung and bronchus cancer with a 5-year survival rate of 18%. Identifying and studying new drug targets are important for improving lung cancer patient survival. 80% to 85% of lung cancers are Non-small cell lung cancer (NSCLC). Knocking down and small molecule inhibition of Superoxide dismutase 1 (SOD1) has been shown to be cytotoxic to cultured NSCLC cells and mouse tumors, suggesting that SOD1 is important for NSCLC survival, thus presenting a promising therapeutic strategy. SOD1 rapidly converts superoxide anion to hydrogen peroxide. It is a critical component of the cellular antioxidant defense system. In addition, our laboratory has recently demonstrated that SOD1 has a novel function as a transcription factor that regulates oxidative stress response genes. Currently, there are no selective SOD1 inhibitors available to study physiological functions of SOD1. In our study, we show that genetically knockout SOD1 resulted in reduced tumor burden in lung cancer mouse model. Using mouse tumor-derived primary cancer cells, we further show that SOD1 is critical for NSCLC cell proliferation and survival. This study reveals novel functions of SOD1 that are of biological and translational significance, and provide further support for SOD1 as a promising therapeutic target for NSCLC. Citation Format: Xiaowen Wang, Justin Wong, Holly Van Remmen, Jessie Yanxiang Guo, Eileen White, X. F. Steven Zheng. SOD1 is required for tumor maintenance in a genetically engineered KRAS/TP53 non-small cell lung cancer mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2421.